All News
Travel During COVID-19 Pandemic
The CDC has addressed the effects and the issues of domestic and international travel on its website. Below is a sampling of key advice.
Read ArticleCopay Assistance Programs Help Patients but Confuse Them Too
"If you're having trouble paying for your medications, Drug Company X may be able to help."
Read Article2020 Rheumatology Year in Review
2020 was historic, memorable and game-changing. Under the cloud of COVID-19, there were many significant and memorable advances and setbacks for the rheumatology world. In our accounting of most read articles for 2020, (not surprisingly) 17/20 were COVID-related.
Read ArticleProDERM Study: IVIG in Dermatomyositis
The ProDERM study design and outcomes are previewed in Medicine; and as promised the results were revealed at ACR Convergence in November 2020 showing that IVIg is safe, effective and superior to placebo i(PBO) in patients with dermatomyositis (DM).
Read ArticleLong Term Safety and Efficacy of Tacrolimus in Lupus Nephritis
Takeuchi et al has published their large experience with long-term tacrolimus use in lupus nephritis patients showing its real-world safety and efficacy.
Read ArticleDelays in Diagnosis of Axial Spondyloarthritis
The diagnosis of axial spondyloarthritis (and anklylosing spondylitis) (axSpA) is often delayed and usually not diagnosed by rheumatologists; a recent metanalysis shows that longer delays were attributable to lower education levels, younger age at onset and absence of extra-articular manifes
Read ArticleHydroxychloroquine Shortage During COVID-19
According to a recent report in Annals of Rheumatic Disease, public enthusiasm for hydroxychloroquine (HCQ) created significant access issues for rheumatic patients in the early phases of the COVID-19 pandemic.
Read ArticleAdipose Transplants as a New Regulator of Osteoarthritis
A novel report from PNAS suggests that in osteoarthritis (OA), the damage is not entirely from body weight and mechanics, instead it may be from adipose tissue itself.
Read ArticleCorticosteroid Use Hikes CV Risks in Rheumatic Patients
UK Clinical Practice Research Datalink population study shows that patients with immune-mediated inflammatory diseases, such as RA, PMR, GCA and IBD, have an augmented risk of CV outcomes with glucocorticoid use; even lower doses had a near doubling of their underlying CVD risk.
Read ArticleMedicare's 'Most Favored Nation' Drug-Pricing Rule in Limbo
The fate of the Trump administration's "most favored nation" (MFN) rule for bringing down prescription drug prices remains uncertain as President-elect Joe Biden prepares to assume office later this month.
Read ArticleRheumNow Podcast – Lights, Camera, Zoom (1.8.2021)
Dr. Jack Cush reviews the news, journal articles and favorite blogs from this past week on RheumNow.com.
Read ArticleAdherence to Hydroxychloroquine Lowers Lupus Mortality
A lupus cohort study from British Columbia, Canada has shown that medication adherence with hydroxychloroquine (HCQ) is associated with a 71% to 83% lower mortality.
Read ArticleRhapsody Study: IL-1 Inhibition in Recurrent Pericarditis
Recurrent pericarditis is a rare, probable autoinflammatory disorder mediated by interleukin-1 (IL-1); and is often refractory to glucocorticoids and colchicine.
Read ArticleEULAR Guidance on Patient Adherence to Meds
Non-adherence may be the single most untold risk to suboptimal outcomes in the care of musculoskeletal disease. It has been estimated that 30-80% of patients with rheumatic and musculoskeletal diseases (RMDs) are nonadherent to prescribed regimens. EULAR has commissioned a task force
Read ArticleCOVID-19 Vaccination - Phase Ib Begins
The U.S. Centers for Disease Control and Prevention (CDC) has issued a timeline guidance document on when, how and who should get the commercially available COVID-19 vaccines.
Read ArticleTelemedicine Less Utilized in the South and Urban Areas
MMWR has reported on a July 2020 survey study from 1,009 Health Resources and Services Administration–funded health centers showing that urban Health centers were more likely to provide virtual visits than those in rural areas.
Read Article
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)


